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Abstract
The clinical success of adoptive immunotherapy of cancer relies on the selection of target antigens that are highly
expressed in tumor cells but absent in essential normal tissues. A group of genes that encode the cancer/testis or cancer
germline antigens have been proposed as ideal targets for immunotherapy due to their high expression in multiple cancer
types and their restricted expression in immunoprivileged normal tissues. In the present work we report the isolation and
characterization of human T cell receptors (TCRs) with specificity for synovial sarcoma X breakpoint 2 (SSX2), a cancer/testis
antigen expressed in melanoma, prostate cancer, lymphoma, multiple myeloma and pancreatic cancer, among other
tumors. We isolated seven HLA-A2 restricted T cell receptors from natural T cell clones derived from tumor-infiltrated lymph
nodes of two SSX2-seropositive melanoma patients, and selected four TCRs for cloning into retroviral vectors. Peripheral
blood lymphocytes (PBL) transduced with three of four SSX2 TCRs showed SSX241-49 (KASEKIFYV) peptide specific reactivity,
tumor cell recognition and tetramer binding. One of these, TCR-5, exhibited tetramer binding in both CD4 and CD8 cells and
was selected for further studies. Antigen-specific and HLA-A*0201-restricted interferon-c release, cell lysis and lymphocyte
proliferation was observed following culture of TCR engineered human PBL with relevant tumor cell lines. Codon
optimization was found to increase TCR-5 expression in transduced T cells, and this construct has been selected for
development of clinical grade viral vector producing cells. The tumor-specific pattern of expression of SSX2, along with the
potent and selective activity of TCR-5, makes this TCR an attractive candidate for potential TCR gene therapy to treat
multiple cancer histologies.
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Introduction
Recent advances in the fields of tumor immunology, cancer
genomics and gene transfer technologies have permitted the
development of therapies based on adoptive transfer of autologous
tumor-reactive T cells for the treatment of human malignancies
[1,2]. Tumor-reactive T cells can be natural, as in the case of
tumor infiltrating lymphocytes (TIL) purified from resected lesions
and stimulated ex vivo, or generated from peripheral blood by
introduction of genes encoding for immune receptors [3].
While the high rate (50–70%) of objective clinical responses
achieved by TIL treatment in patients with advanced-stage
melanoma established a solid proof of concept for the treatment
of human cancers with T cells [4,5], its widespread application is
limited by the difficulty in culturing and expanding these T cells to
clinically relevant numbers for every patient. As an alternative
approach, the antigen specificity of readily available peripheral
blood T cells can be redirected to antigens expressed in tumor cells
by genetic modification. Adoptive transfer of autologous T cells
engineered to express T cell receptors (TCRs) or antibody-derived
chimeric immune receptors can result in a potent cellular immune
response against tissues expressing the target antigens, even at low
levels [3,6–8]. It is therefore instrumental to carefully select
antigens that are expressed in tumor cells but absent from essential
normal tissues, in order to avoid undesired on-target/off-tumor
toxicities.
Current efforts in identifying the optimal target antigens for
adoptive immunotherapy are mainly focused on the neoantigens
generated by somatic mutations present in tumors but absent in
normal tissues [9,10], on antigens expressed on dispensable
normal tissues, and on a group of genes that encode for the
cancer-testis (CT) antigens. The latter are defined by their pattern
of expression which, in adults, is generally restricted to non-MHC
expressing germ cells of testis, that thus do not present antigens to
T cells, and to tumor cells of diverse origin [11–13]. Adoptive
transfer of autologous peripheral blood lymphocytes expressing a
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TCR specific for a cancer-testis antigen, NY-ESO-1, mediated
objective tumor regressions in patients with advanced melanoma
and with synovial cell sarcoma, with no NY-ESO-1 related toxicity
[14].
In order to expand the repertoire of antigens that can be
targeted by this approach, therefore expanding the number of
patients and tumor types that can be treated, we developed a
TCR-expressing vector targeting a member of the synovial
sarcoma X breakpoint family, SSX2. The synovial sarcoma X
breakpoint (SSX) genes are located on the X chromosome and
encode a family of ten highly homologous nuclear proteins, SSX1–
10. SSX2 was originally identified as part of a genomic
translocation present in synovial sarcoma [15,16] and later found
to be identical to HOM-MEL-40, an immunogenic protein known
to induce spontaneous antibody responses in 10% of patients with
melanoma [17].
We generated retroviral vectors encoding the TCR alpha- and
beta-chains targeting the HLA-A*0201-restricted epitope SSX241-
49, isolated from previously described melanoma patients display-
ing active immune responses to SSX2 [18]. We further
demonstrated that T cells engineered with these vectors recognize
cell lines derived from multiple cancer histologies. Optimization of
TCR expression and activity by modification of its nucleotide
sequence allowed us to identify the optimal design for efficient
expression and potent antigen-specific reactivity against SSX2.
Production of a clinical-grade retroviral vector producer cell line
was further pursued for its future application in adoptive
immunotherapy clinical trials.
Materials and Methods
Cell lines and human PBLs
HLA-A*0201+/SSX2+ melanoma cell line 624, and non-HLA-
A*0201 cell lines 888 and 938 were established from surgically
resected metastatic melanoma tumors and maintained at the
Surgery Branch, National Cancer Institute, National Institutes of
Health (Bethesda, MD). The HLA-A*0201+/SSX2+ glioma cell
line U251 was obtained from the Division of Cancer Treatment
and Diagnosis Tumor Repository, National Cancer Institute,
National Institutes of Health (Frederick, MD). Melanoma lines
SKmel23 and SKmel37, and breast cancer cell line MCF7 were
purchased from ATCC (Manassas, VA). Cos7-A*0201 and 293-
A*0201 cells were retrovirally engineered to express HLA-A*0201
as described previously [19,20]. Cos7-A*0201-SSX2 and 293-
A*0201-SSX2 cells were transduced with a retroviral vector
expressing the cDNA of SSX2. T2 is a lymphoblastoid cell line
lacking TAP function, whose HLA class I proteins can be easily
loaded with exogenous peptides. PG13 packaging clones were
generated using the PG13 gibbon ape leukemia virus packaging
cell line (ATCC CRL-10686), and the human ecotropic packaging
cell line, Phoenix ECO (kindly provided by Dr. Hans-Peter Kiem,
Fred Hutchinson Cancer Research Center, Seattle, WA). All cells
were cultured in D10 medium consisting of high-glucose (4.5 g/L),
Dulbecco’s modified essential medium (DMEM, Invitrogen,
Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS,
Hyclone, Logan, UT) and 6 mM glutamine (final concentration;
Invitrogen, Carlsbad, CA). Cells were maintained at 37uC and 5%
CO2.
Peripheral blood lymphocytes used in this study were obtained
from melanoma patients treated in the Surgery Branch, National
Cancer Institute, National Institutes of Health, on NCI Institu-
tional Review Board-approved protocols. Patients provided
written consent for procurement of tissues and use of these for
research purposes, as detailed in protocol 03-C-0277. Human
lymphocytes were maintained in AIM-V medium (Invitrogen,
Carlsbad, CA) supplemented with 5% human AB serum (Valley
Biomedical, Winchester, VA), 50 U/mL penicillin, 50 mg/mL
streptomycin (Invitrogen), and 300 IU/mL IL-2 and maintained
at 37uC with 5% CO2. SSX2 specific T cell clones were newly
generated from tumor infiltrated lymph node-derived T cells of
patients Lau 567 and Lau 672, similarly as described previously
[18].
Synthetic peptides
The SSX241-49 peptide (KASEKIFYV) corresponding to amino
acids 41 to 49 of SSX2, and homologous peptides derived from
SSX1 (KYSEKISYV), SSX3 (KVSEKIVYV), SSX4 (KSSEKI-
VYV), SSX5 (KASEKIIYV), SSX6 (KFSEKISCV), SSX7
(KSLEKISYV), SSX8 (KYSEKISYV), SSX9 (KSSEKIIYV),
SSX10 (KASEKILYV), IGSF22 (KESAKIFYD), ARHGAP1
(KFGQKIFYV), GPR82 (SCYEKIFYG), PHF8 (LKGEKIFYL),
LIPM (TGQEKIYYV), SYT14 (IVGEKIFYL), TCOF1 (KASE-
KILQV), RBL2 (SPREKIFYY) and FRAS1 (SPREKIYYV) were
synthesized by GenScript (Piscataway, NJ). Peptides were dissolved
in DMSO and diluted in RPMI 1640 medium for loading of T2
cells. Binding affinity to HLA-A2*0201 was predicted for each
peptide using NetMHC-3.0 [21]. Identification of peptides
homologous to SSX241-49 with a potential for cross-reactivity
was performed by blast search (blastp algorithm).
Construction of retroviral vectors for the expression of
SSX2–specific HLA-A*0201–restricted TCRs
MSGV1-based retroviral vectors were constructed by overlap-
ping PCR with the alpha- and beta-TCR chains arranged in the
following order: TCR alpha-chain, linker peptide furin-
SGSGP2A, TCR beta-chain, as previously described [22]. The
cloned TCR inserts were verified by restriction enzyme profiling
and direct DNA sequencing. The cDNA encoding for the codon-
optimized version of the SSX2-specific TCR and a codon-
optimized TCR with murine constant regions were synthesized by
GenScript. The human-mouse hybrid version of TCR-5 was
designed as previously described [23].
T cell transduction
Retroviral supernatants were generated by transfecting each
pMSGV1-SSX2-TCR plasmid along with a vector encoding
RD114 envelope into 293-GP cells using the Lipofectamine 2000
reagent (Invitrogen) in Opti-MEM medium (Invitrogen) [22].
Viral supernatants were then loaded onto RetroNectin-coated
(Takara Bio, Japan) non-tissue culture-treated six-well plates. PBLs
were stimulated with OKT3 (50 ng/mL) and rhIL-2 (300 IU/mL)
48 h prior to transduction, and the transduction was carried out as
described previously [24].
Tetramer staining
HLA-A*0201–restricted SSX2–derived peptide SSX241-49 (KA-
SEKIFYV) were produced by the National Institutes of Health
Tetramer Core Facility at Emory University (Atlanta, GA) using
phycoerythrin (PE) as the fluorochrome. For evaluation of TCR
transduction efficiency in T cell subsets, transduced T cells were
stained with a FITC-labeled anti-human CD8 (BD Pharmingen,
San Jose, CA) and with PE-labeled HLA-A*0201 tetramers. Cells
were analyzed using a FACScan flow cytometer with CellQuest
software (BD Biosciences) or FlowJo software (Tree Star, Ashland,
OR).
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Cytokine release assay
TCR-transduced lymphocytes were tested for antigen-specific
reactivity in cytokine release assays using peptide-loaded T2 cells
or tumor cells. To that end, effector cells and target cells were
cocultured at a 1:1 ratio (16105 of each) in 200 uL of AIM-V
medium in duplicate wells of a 96-well microplate. Culture
supernatants were harvested 18–24 h after the initiation of
coculture and assayed for interferon-c (IFNg) by ELISA (Thermo
Scientific).
[51Cr] release assay
The ability of the transduced PBLs to lyse HLA-A*0201+
SSX2+ tumor cells was assessed using a standard [51Cr] release
assay as described previously [25] Briefly, TCR-engineered PBLs
were cultured with decreasing ratios of 51Cr-labeled target cells
(E:T ratio) in AIM-V medium in 96-well U plates at 37uC for 4 h.
Lysis was measured by [51Cr] release in the medium according to
the formula: percent lysis = (sample release - minimum release)/
(maximum release - minimum release) x 100%. Results expressed
as average of duplicate samples.
Generation of a PG13 packaging clone encoding an
SSX2-specific TCR
A PG13 retroviral packaging cell clone was generated as
described previously with the following changes [24]. Phoenix
ECO cells were transfected with 9.5 mg of plasmid DNA
(pMSGV1-SSX2.567.5-co) using the Lipofectamine 2000CD
transfection reagent (LifeTechnologies, Carlsbad, CA). After
48 h supernatant was harvested and used to transduce retroviral
packaging cell line, PG13. Non-tissue culture treated 6-well plates
coated with 20 mg/mL RetroNectin as described by the manu-
facturer. Retroviral vector supernatant (4 mL) was added to each
well followed by centrifugation (20006g) at 32uC. After 2 h,
supernatant was removed and 56105 PG13 cells were added to
the well, centrifuged (10006g) for 10 min at 32uC. Two rounds of
transduction were performed and then PG13 packaging clones
were generated by limiting dilution cloning. Due to lack of a
selectable marker, high titer clones were identified by RNA dot
blot as described previously [24,26]. Retroviral vector from the 6
highest titer clones was generated as described. Briefly, 175 cm2
tissue culture flasks (Nunc, Cole-Parmer, Vernon Hills, IL) were
seeded at 46104 cells/cm2, followed by a medium exchange
(30 mL) on day 3. Supernatant was harvested 24 h later, aliquoted
and stored at 280uC until further use. Supernatant from each
clone was evaluated for the ability to efficiently transduce human
PBL and elicit IFNg in a cytokine release assay. A high titer clone
will be selected for production of a master cell bank and
subsequent GMP retroviral vector supernatant.
Generation of GMP retroviral vector supernatant
A total of 26 1700 cm2 expanded surface roller bottles were
seeded on day 0 at a cell density of 46104 cells/cm2 in 200 mL of
D10 medium. On day 3, the medium was exchanged and replaced
with 120 mL D10 medium. Medium containing the retroviral
vector was harvested daily with bottles being refed with 120 mL of
medium. Glucose levels were monitored daily using Roche’s Accu-
check system (Roche, Basal, Switzerland). If glucose levels dropped
below 2 g/L, the volume of the medium exchange was doubled to
240 mL/roller bottle for all subsequent harvests. All harvests were
aliquoted and stored at 280uC until further use. An aliquot from
each harvest was tested for transduction efficiency and cytokine
release as described previously. All clinical products were subjected
to an extensive biosafety testing program in accordance with
current regulatory guidelines (US Food and Drug Administration,
Center for Biologics Evaluation and Research; reference Points to
Consider in the Production and Testing of New Drugs and
Biologicals Produced by Recombinant DNA Technology, 1985;
Points to Consider in the Characterization of Cell Lines Used to
Produce Biologicals, 1993; Guidance for Industry: Guidance for
Human Somatic Cell Therapy and Gene Therapy, 1998;
Guidance for Industry, INDs – Approaches to Complying with
CGMP During Phase I, 2006).
Results
Cloning of human SSX2-reactive TCRs
The coding regions of TCR alpha- and beta- chains were
cloned from previously described naturally occurring SSX2-
reactive T cells from two melanoma patients [18]. These HLA-
A2-restricted CD8 cells recognize an epitope spanning residues 41
to 49. cDNA was synthesized by 59RACE using primers specific
for the constant region of TCR genes and the products were
sequenced, identifying seven different pairs of TRAV and TRBV
genes (table 1). Expression cassettes containing the alpha- and
beta-TCR chains separated by the 2A linker peptide [27,28] were
generated by overlapping PCR and cloned in to pMSGV1 for
generation of retroviral expression vectors for clones 5, 8, 9 and 11
(figure 1A).
Expression of cloned TCRs in human lymphocytes
Retroviral vector supernatants were generated by transient
transfection of 293GP and used for transduction of OKT3-
stimulated human T cells. Expression and correct assembly of
TCRs was evaluated by flow cytometry, using fluorescently labeled
HLA-A2-SSX241-49 tetramers. TCR5 was efficiently expressed in
both CD8 and CD4 cells, TCR9 and TCR11 were expressed only
in CD8 cells, while expression of TCR8 was not detected by this
technique (figure 2 A).
Reactivity of PBL transduced with human anti-SSX2 TCRs
against SSX2-positive tumor cells
The correct processing and presentation of the SSX241-49
epitope, and recognition by TCR-engineered PBL were tested in
vitro by culturing the PBL with derivatives of Cos-7 and HEK293
cells that express HLA-A*0201 with or without concomitant
expression of the antigen SSX2 (Cos-A2, Cos-A2 SSX2, 293-A2
and 293-A2 SSX2, respectively). As shown in figure 2B, T cells
transduced with TCR-5, -9 and -11 secreted high levels of IFNg
(in the order of 16104 pg/mL) when cocultured with SSX2-
transfectants. TCR-8-transduced T cells secreted only background
levels of IFNg, in line with the lack of tetramer binding shown in
figure 2A. In order to verify the HLA-A*0201 restriction of these
TCR, an SSX2-positive HLA-A*0201-negative melanoma cell
line (938) or its derivative engineered to express HLA-A*0201
(938-A2) were used as targets for coculture experiments. As shown
in figure 2C, lymphocytes expressing TCR-5, -9 and -11 secreted
IFNg only when cultured in presence of 938-A2 cells. Recognition
of 938-A2 endogenous SSX2 was stronger in TCR-5-transduced
lymphocytes, as evidenced by a 2-fold higher IFNg secretion by
those cells compared to that of T cells transduced with TCR-9 and
-11 (figure 2C).
To test the ability of these TCRs to recognize the endogenous
SSX2 expressed by tumor cells, we cultured PBLs (transduced with
TCR-5, -8, -9, -11) with cell lines derived from melanoma (888,
SKMEL-23, 624), glioma (U251), and breast cancer (MCF-7). As
shown in figure 2D, TCR-5, -9 and -11 mediated IFNg release by
transduced lymphocytes when cultured in presence of HLA-
HLA-A*0201-Restricted TCR against SSX2
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A*0201-positive SSX2-positive tumor cells from glioma and
melanoma. Of note, TCR-5 mediated the strongest target
recognition among the different TCRs test. Based on this, and
on its efficient expression in both CD8 and CD4 T cells, we
selected TCR-5 for further characterization.
Cross-reactivity with other members of the SSX family
and non-SSX proteins
The SSX family comprises 10 genes encoding proteins that are
highly homologous to each other. In particular, the epitope of
SSX2 targeted by TCR-5 lies within one of the regions of
homology between members of the family. As shown in figure 3A,
the amino acid sequence of SSX5 and SSX10 differ from SSX241-
49 in only one residue; SSX1, SSX3, SSX4, SSX8 and SSX9 differ
from SSX241-49 in two amino acids; and SSX6 and SSX7 differ
from SSX241-49 in three amino acids. In addition to SSX2, SSX3
and SSX5 were predicted to bind HLA-A2 molecules with high
affinity. Peptides derived from SSX4, SSX7, SSX9 and SSX10
were predicted to bind to HLA-A2 with lower affinity. Reactivity
of TCR-5 against each of these peptides was tested in coculture
experiments using human lymphocytes expressing TCR-5 as
effectors and peptide-pulsed T2 cells as targets, and secretion of
IFNg was assessed as a marker of antigen recognition. While
TCR-5-expressing cells secreted IFNg upon exposure to SSX241-49
at low concentration of peptide (.0.01 ng/mL), they reacted to
SSX3-, SSX4-, SSX5-, SSX9- and SSX10-derived peptides only
when exposed to high concentrations of peptide (over 10 ng of
peptide/mL, figure 3 A). This difference in reactivity of three to
four orders of magnitude indicates that TCR-5 is relatively specific
for SSX241-49, and suggests that recognition of cells expressing
homologous peptides derived from other SSX genes may be
unlikely.
Nine additional protein-encoding genes were identified by blast
search as partially homologous to the SSX241-49 epitope: IGSF22,
ARHGAP1, GPR82, PHF8, LIPM, SYT14, TCOF1, RBL2 and
FRAS1. The overlapping peptides in two of these proteins,
IGSF22 and TCOF1, differed in only two residues from the
targeted SSX2 epitope. In addition, peptides derived from SYT14
and TCOF1 were predicted to be strong and weak HLA-A2
binders, respectively (figure 3B). We analyzed the recognition of
these nonamer peptides by TCR-5 in coculture experiments using
peptide-pulsed T2 cells. As depicted in figure 3B, IFNg release
induced by SSX241-49 peptide was two to four orders of magnitude
superior to that induced by the homologous peptides, confirming
the specificity of TCR-5.
Codon optimization and murinization of TCR-5
We next evaluated whether optimization of codon usage in the
coding sequence of TCR-5 and/or the use of human-mouse
hybrid TCRs could enhance TCR-5 expression and/or biological
activity. cDNA encoding for the same amino acid sequence as
TCR-5 but with a nucleotide sequence optimized for codon usage
Figure 1. Generation of retroviral vectors for the expression of SSX2-specific TCRs. The coding region of each TCR alpha-chain was
amplified by PCR using primers flanked by an NcoI restriction site in the 59 end and an overhanging sequencing containing the element in the 39 end.
In parallel, each TCR beta-chain was amplified by PCR using a forward primer containing a 59 overhang that overlaps with the 39 overhang present in
the primer used for the amplification of the alpha-chain. The reverse primer used for amplification of the beta-chain contained a stop codon and an
EcoRI restriction site. In a second round of PCR, the products of the alpha- and beta-chain amplifications were pooled, and ligation of both cDNA
fragments through the overlapping overhangs was achieved by PCR using external primers. The resulting PCR products were cloned in pMSGV1
vector for retrovirus production. LTR: long terminal repeat, sd: splice donor, sa: splice acceptor, y: retrovirus encapsidation signal.
doi:10.1371/journal.pone.0093321.g001
Table 1. TCRs isolated from SSX2-reactive lymphocyte clones.
Patient T cell clone TRAV TRBV
Lau 567 5 14/DV4*01 15*02
8 23/DV6*02 10-3*01
10 17*01 15*02
Lau 672 7 12-2*02 7-9*01
9 5*01 20-1*01
11 12-1*01 2*01
14 21*02 19*01
TRAV: TCR alpha-chain variable region.
TRBV: TCR beta-chain variable region.
doi:10.1371/journal.pone.0093321.t001
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in humans was synthesized and cloned in pMSGV1 for generation
of retroviral vectors. Similarly, a codon-optimized version of TCR-
5 in which the TCR constant regions were replaced with the
constant region of a mouse TCR [23] was synthesized and cloned
in pMSGV1. The three versions of TCR-5 (WT, codon optimized,
and codon optimized + mouse constant region, figure 4A) were
next compared in their expression and ability to recognize antigen
and mediate cell lysis.
After retroviral transduction of OKT3-stimulated human
lymphocytes, tetramer staining was used to evaluate the expression
of the three constructs. As shown in figure 4 B, codon optimization
increased the density of membrane expression of TCR in CD8 T
cells as evidenced by an increased mean fluorescence intensity
(MFI) of SSX241-49 tetramer staining in cells transduced with the
codon-optimized TCR-5 (910 fluorescence units), compared to
those transduced with the wild-type version (656 fluorescence
units). However, use of a murine constant region in addition of
codon optimization only minimally increased the tetramer binding
by the TCR (949 fluorescence units). The biological activity of the
TCRs was tested in coculture experiments where the TCR-
transduced lymphocytes were exposed to multiple HLA-A*0201-
positive target cells that were positive for SSX2 (Cos-A2-SSX2,
293-A2-SSX2, K562-A2, 624, 938-A2 and U251). The concen-
tration of IFNg in the supernatants was measured by ELISA after
an overnight coculture and the results are shown in table 2.
Lymphocytes transduced with the codon-optimized version of
TCR-5 secreted, on average, 30% more IFNg than those
transduced with the wild-type TCR. The presence of a mouse
TCR constant region also increased IFNg secretion compared to
the wild-type TCR, but this modification did not increase the
IFNg secretion of the codon-optimized variant (table 2). The three
constructs displayed similar properties in terms of induction of
antigen-specific proliferation of T cells in thymidine uptake assays
(figure S1A), T cell activation upon antigen recognition (evidenced
by up-regulation of the activation marker CD137, figure S1B) and
interleukin-2 (IL-2) production (figure S1C).
Induction of cell lysis of tumor cells expressing SSX2
The ability of each variant of TCR-5 to induce antigen-specific
cell lysis of tumor targets by human lymphocytes was determined
using a chromium release assay. Chromium (51Cr)-labeled 938,
938-A2, Cos-A2, Cos-A2-SSX2, 624, SKmel37 and 888 cells were
cocultured with human peripheral blood T cells transduced the
wild-type TCR-5 or its codon-optimized or codon-optimized
murinized variants, at different effector:target ratios. Untrans-
duced T cells were used as negative control. As depicted in figure 4
C, lymphocytes transduced with either of the SSX241-49-specific
TCRs induced potent cytolytic effect on 938-A2 cells but not on
938 cells, indicating that lysis is HLA-A*0201-restricted. In
addition, Cos-A2-SSX2 cells were lysed by TCR-5-expressing
cells, but not Cos-A2, which lack expression of SSX2, indicating
that this effect is antigen-specific. Similarly, 624 and SKmel37
cells, which are HLA-A*0201 positive and naturally express SSX2,
were lysed by lymphocytes transduced with either TCR-5 variant,
whereas HLA-A*0201-negative 888 cells were not. Together,
these results confirm that TCR-5-derived constructs are biologi-
cally functional in human peripheral blood T cells, and that they
can be used to redirect their antigen specificity to SSX2, in an
HLA-A*0201-specific fashion. Neither codon optimization or
murinization of TCRs had an effect on TCR-5-mediated lysis.
Development and testing of clinical grade retroviral
vector supernatants
Due to the tumor-selective pattern of expression of SSX2, and
the potent yet selective antigen-recognition properties of TCR-5,
we decided to produce and test clinical-grade retroviral vectors
suitable for the expression of TCR-5 in peripheral blood T cells of
cancer patients. Stable packaging lines were established by
transduction of PG13 cells with a retroviral vector encoding the
codon-optimized version of TCR-5. After two transductions,
PG13 cells were cloned by limiting dilution and clones were tested
for viral RNA expression using dot–plot (not shown). The six
clones expressing the highest levels of vector RNA (A8, A10, C3,
D8, F2 and H2) were amplified and the supernatants were tested
for their ability to induce TCR expression in OKT3-stimulated
PBL from three different donors. Tetramer staining of transduced
T cells revealed that supernatants of the six clones mediated
efficient transduction of lymphocytes (figure 5 A). The average
percentage of transduction of clones A8 A10, C3, D8, F2 and H2
(taking CD8 and CD4 T cells together) were 61.7%, 60.3%,
58.0%, 65.3%, 52.3% and 63.7%, respectively. In agreement with
their similar transduction efficiency, supernatants of all clones
induced reactivity against HLA-A*0201-positive SSX2-expressing
624 cells when tested in coculture assays (figure 5 B). IFNg release
after overnight coculture of 16105 lymphocytes with 16105
624 cells was (5023+/- 295) pg/mL, whereas transduced lympho-
cytes released only background levels of IFNg when exposed to
HLA-A*0201-negative 938 cells or SSX2-negative CosA2 cells.
Together, these results document the development of a clinical
grade reagent for TCR-based adoptive immunotherapy of human
malignancies, targeting the cancer-testis antigen SSX2 using a
codon-optimized TCR derived from a melanoma patient.
Discussion
Cancer-testis antigens have been proposed as ideal targets for
adoptive immunotherapy of cancer due to their over expression in
tumor cells of multiple histologies and restricted expression in
normal tissues [11]. Although SSX2 is expressed in male germ
cells, the lack of expression of MHC molecules by these cells
prevents antigen presentation on the cell surface. We focused on
one specific cancer-testis antigen, synovial sarcoma X breakpoint
(SSX)2, a gene initially described as part of chromosomal
rearrangements commonly found in synovial sarcoma cells:
SYT-SSX2 [29] and SS18-SSX2 [30] translocations. The gene
products resulting from these translocations have been shown to
act as epigenetic modulators and to regulate cell growth,
proliferation, cell death, potentially contributing to oncogenesis
[30]. The physiological function of wild-type SSX2, however, is
largely unknown.
SSX2 expression has been documented on prostate cancer
[31,32] and in multiple myeloma [33,34] in addition to melanoma
Figure 2. Expression and biological function of SSX2 TCR-5, -8, -9 and -11. A) Analysis of surface expression of SSX241-49-specific TCRs in
CD8 and CD4 T cell populations by flow cytometry. Human peripheral blood mononuclear cells were stimulated with OKT3 and transduced with the
indicated retroviral expression vectors. One week later, cells were stained with anti-human CD3, CD8 antibodies and with a fluorescently labeled
tetramer containing the SSX241-49 peptide. Results from one representative donor of at least four independent experiments. Events gated on
lymphoid, single, viable, CD3+ cells. B) – D) Concentration of IFNg in supernatants of TCR-transduced T cells cultured overnight with the indicated
targets (16105 effectors vs 16105 targets). Results shown as average of duplicates for two representative donors out of four. UT: untranduced.
doi:10.1371/journal.pone.0093321.g002
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Figure 3. Analysis of recognition of other genes by TCR-5. Peripheral blood T cells expressing TCR-5 were cocultured overnight with T2 cells
previously pulsed with the serial dilutions of the indicated peptides. Results of IFNg concentration in culture supernatants are expressed as average of
duplicates in a representative experiment. Sequence alignment of the tested peptides is shown in the figure legend for A) SSX-family genes and B)
non-SSX genes with overlapping sequences. IGSF22: immunoglobulin superfamily member 22, ARHGAP1: Rho GTPase-activating protein 1, GPR82:
Probable G-protein coupled receptor 82, PHF8: histone lysine demethylase PHF8, LIPM: lipase member M, SYT14: synaptotagmin-14, TCOF1: treacle
protein, RBL2: retinoblastoma-like protein 2, FRAS1: extracellular matrix protein FRAS1. Prediction of binding affinity to HLA-A2*0201 is shown for
each peptide, expressed as dissociation constant (KD, nM).
doi:10.1371/journal.pone.0093321.g003
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Figure 4. Codon optimization and replacement of TCR constant regions with murine sequences. A) Schematic representation of the
three constructs generated for the expression of TCR-5 and derivatives. LTR: long terminal repeat, sd: splice donor, sa: splice acceptor, y: retrovirus
encapsidation signal, MC: mouse TCR constant region, 2A: linker peptide. B) Analysis of expression of TCR-5 variants by tetramer staining. OKT3-
stimulated lymphocytes were transduced twice with the corresponding TCR-expressing vector and stained with anti-CD3, anti-CD8 and SSX241-49
tetramers one week after transduction. Representative results from three independent experiments. Values in parentheses represent the mean
fluorescence intensity of tetramer staining within the CD8 T cell population. C) 51Cr-release assay for the evaluation of antigen-specific cytolysis
induced by TCR-5-transduced lymphocytes after four-hour coculture with the indicated target cells. Percentage of lysis depicted for each target cell
line at different effector:target ratios is the average of duplicates in a representative experiment of three independent experiments. UT: untransduced
T cells used as negative control of unspecific lysis, WT: Wild-type TCR, Co Op: copon-optimized TCR, MCR: codon-optimized TCR with mouse constant
region.
doi:10.1371/journal.pone.0093321.g004
Table 2. IFNg secretion (pg/mL) by TCR-5 transduced lymphocytes upon coculture with indicated targets.
Target cell line Histology TCR-5
UT WT Codon Optimized
Codon optimized +
mouse constant
region
Cos-A2-SSX2 Kidney (Monkey) 615 52577 64142 56893
293-A2-SSX2 Kidney 515 29804 37522 37258
K562-A2 Erythroleukemia 1830 12542 21325 17437
SKmel37 Melanoma 96 6635 8869 10401
624 Melanoma 453 27344 37547 46999
938-A2 Melanoma 626 37032 46304 51092
U251 Glioma 372 16653 19223 19027
SKOV3 Ovarian cancer 877 2414 2527 2221
doi:10.1371/journal.pone.0093321.t002
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[17]. Initial studies by Tureci et al showed SSX2 mRNA was
expressed in 50% of melanomas, 30% of hepatocarcinomas, 25%
of colon cancers, and 20% of breast carcinomas [17]. Dubovsky
and McNeel reported that SSX2 mRNA was expressed in testis,
but undetectable in liver, lung, colon, bladder, heart, brain,
kidney, placenta, skeletal muscle, spleen, thymus, or prostate, by
RT-PCR [10]. Similarly, no expression was detected in five
normal prostate epithelial cell lines, but SSX2 mRNA was
expressed by LAPC4 and MDA-PCa-2b prostate cancer cell lines.
Interestingly, SSX2 mRNA expression was increased by treatment
with demethylating agent 5-aza-29deoxycytidine (AZA) in the
prostate cancer cell lines LNCAP and DU145 but not in the
normal prostate epithelial cell line RWPE-1 [10]. More recently,
Smith et al performed an immunohistochemical analysis of prostate
cancer resections using an antibody that recognizes both SSX2
and SSX3. They found that 25% of metastatic lesions were
positive for SSX2/3, but normal prostate and primary lesions were
negative [31,32].
Dos Santos et al detected SSX2 mRNA expression in nine of
eighteen melanoma cell lines by RT-PCR, and positive staining in
34 of 101 melanoma lesions using a monoclonal antibody that
recognizes SSX2, SSX3 and SSX4 proteins [35]. Taylor et al.
reported the detection of SSX2 mRNA in 24% of bone marrow
samples of multiple myeloma patients (total: 114) [36], while
Atanackovic et al. detected SSX2 in 12%–16% of bone marrow
samples with significant plasma cell infiltration, but not in bone
marrows of healthy donors [33,37]. This expression across
different cancer histologies makes SSX2 an attractive target that
may allow for treatment of patients with different diagnoses using
a single clinical grade reagent. Curative treatment options for
patients with metastatic androgen-independent prostate cancer or
multiple myeloma are currently scarce, highlighting the need for
novel treatment modalities [38,39]. In this context, adoptive
immunotherapy targeting SSX2 might have a substantial impact
in the clinical management of such diseases.
The SSX2 protein can induce spontaneous immune responses
in cancer patients. Evidence of SSX2 immunogenicity includes the
detection of SSX2-specific antibodies in the serum of patients with
melanoma, colon cancer and breast cancer [40] and the presence
of CD8 T cells with specificity for SSX2 in tumor-infiltrated lymph
nodes of patients with melanoma and hepatocarcinoma [41,42].
These CD8 T cells recognized an epitope spanning residues 41–49
Figure 5. Analysis of expression and biological function of codon-optimized TCR-5 in human lymphocytes transduced with clinical
grade retroviral vector supernatants. A) Flow cytometry analysis of tetramer staining of T cells transduced with vector supernatants produced
by stable packaging line clones A8, A10, C3, D8, F2 and H2. Clones were previously selected as those displaying the highest expression of viral RNA
using dot plot analysis. Results of tetramer and CD8 staining of T cells are shown for three patients. B) IFNg ELISA of supernatants from cocultures of T
cells transduced with vectors derived from clones A8, A10, C3, D8, F2 and H2. HLA-A*0201+ SSX2+ melanoma cells 624, HLA-A*0201- SSX2+
melanoma cells 938 and HLA-A*0201+ SSX2- cells CosA2 were used as targets.
doi:10.1371/journal.pone.0093321.g005
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of SSX2, in a HLA-A*0201-restricted fashion and were found to
be selectively expanded in patients with SSX2-expressing cancers
[18,42]. In the present study we sought to isolate the SSX241-49-
specific TCRs expressed by the CD8 T cells of those patients, and
to develop and characterize retroviral vectors for the expression of
those TCRs in human peripheral blood T cells. This strategy
would allow us to by-pass the induction of a natural immune
response against SSX2 by generating large numbers of T cells with
specificity for this antigen, that could potentially be used for
adoptive cell transfer studies.
A total of seven pairs of TCR alpha- and beta-chains were
identified from melanoma patients Lau 567 and Lau 672. The
cDNA encoding for four of these TCRs were cloned in retroviral
expression vectors and tested for expression in transduced human
T cells and for biological activity. While the TCRs derived from
clone 5 of patient Lau 567 and clones 9 and 11 of patient Lau 672
were efficiently expressed in CD8 T cells upon retroviral
transduction, the TCR isolated from clone 5 (TCR-5) was
expressed, and functionally active, in both CD8 and CD4 T cell
populations, despite having been derived from a CD8 T cell clone.
This characteristic may allow for the generation of more potent
immune responses against SSX2 by activating both the cytolytic
function of CD8 T cells and the cytokine-secreting ability of CD4
T cells [43,44].
Smith and collaborators isolated T cells that recognized a SSX2
epitope spanning residues 103–111, from a prostate cancer
patient. These T cells, however, also recognized the equivalent
epitope in SSX-3, -5 and -9 [31,32]. The remarkable specificity of
TCR-5, even among highly homologous peptides derived from
other SSX family members, has important implications in terms of
safety. This is relevant considering that a TCR directed against
another cancer-testis antigen, MAGE-A3, previously generated in
our laboratory [45] induced tumor regression but also severe
neurotoxicity in a Phase I clinical trial of adoptive immunother-
apy. These adverse events were likely due to cross-reactivity
against an epitope present in MAGE-A12, which has previously
unreported expression in a small subset of neurons [46]. This
epitope of MAGE-A12 differed from the MAGE-A3 epitope
targeted by the TCR in only one amino acid, but this difference
was associated with a significant increase in the affinity of binding
to HLA-A2. In fact, the MAGE-A12-derived peptide was
recognized by the MAGE-A3 TCR with higher avidity than the
MAGE-A3 peptide [46]. Such cross-reactivity against other
members of the SSX family is unlikely to occur in vivo with
SSX2 TCR-5, because the binding affinities of this TCR for the
related peptides was at least three orders of magnitude lower than
the affinity for SSX241-49, in in vitro experiments.
Several modifications can be introduced in the TCRs in order
to increase their affinity or avidity for their cognate antigens. In
the present study we analyzed two ways of potentially increasing
the expression of functional TCRs in the surface of transduced T
cells: codon optimization and codon optimization plus replace-
ment of the constant region of the TCR chains with the constant
regions of murine origin. Optimization of codon usage for
expression in human cells was found to increase both the surface
expression of the SSX2-specific TCRs in transduced T cells and
the reactivity of these T cells against SSX2-expressing targets. We
had previously shown that replacement of the TCR constant
region by constant regions of murine origin could increase the
TCR expression and prevent mispairing of the inserted TCR
chains with the endogenous TCR molecules, potentially prevent-
ing the generation of toxic neospecificities [23]. The theoretical
possibility of off-target toxicity resulting from those neospecificities
has prompted researchers to develop multiple strategies to prevent
mispairing, including transcriptional silencing [47] or genetic
ablation [48] of endogenous TCR expression. In the case of SSX2
TCR-5, no additional increase in expression, tetramer binding or
activity was provided by usage of murine constant regions,
suggesting that mispairing is negligible if at all existing. The three
versions of TCR-5 displayed similar properties in terms of
proliferation in response to antigen stimulation and cytolytic
capabilities. Therefore, we selected the codon-optimized version of
TCR-5 for further development, in order to prevent potential
antibody responses against murine sequences that may inhibit the
activity of TCR gene-modified cells [49]. Amino acid modifica-
tions can also be introduced in the complementarity determining
regions (CDR) of TCRs to enhance their affinity for a given target
[45,50]. Such modifications, however, can induce the recognition
of non-related proteins [50], making it complicated to predict
potential cross-reacting peptides. A more extensive preclinical
evaluation of tissue recognition would therefore be required
involving, for instance, coculture experiments with multiple cell
types derived from induced pluripotent stem cells [50]. One
advantage of non-modified human TCRs such as TCR-5 is that
they have undergone thymic negative selection of self-reactive
clones, and therefore are less likely to recognize vital self-tissues.
An important feature of cancer-testis antigens is that their
expression can be induced by epigenetic modification of the tumor
cells as a consequence of treatment with pharmacological agents.
For instance, treatment with demethylating agents such as AZA
and/or histone deacetylase inhibitors such as depsipeptide have
been shown to increase the levels of expression of NY-ESO-1 in
melanoma cells, leading to increased recognition by T cells
transduced with anti-NY-ESO-1 and anti-MAGE-A3 TCRs
[22,41]. Therefore, the development and characterization of
retroviral vectors expressing SSX2 TCR-5 as a clinical grade
reagent open a wide array of possibilities in the design of adoptive
immunotherapy of cancer. These include not only the utilization
of autologous T cells transduced with SSX2 TCR-5 as a single
agent, but also combination therapies consisting of sequential
administration of demethylating agents and/or deacetylase inhib-
itors with T cells targeting one or more cancer-testis antigens [51].
A careful validation of the optimal dosage and scheduling would
be necessary to guarantee the induction of the expected synergism
between the two parts of the treatment.
Supporting Information
Figure S1 Antigen-driven proliferation and activation of
human T cells expressing either wild-type, codon-
optimized or codon-optimized ‘murinized’ TCR-5. A)
Proliferation of TCR-5-transduced lymphocytes after coculture
with CosA2-SSX2 cells during three days. Values represent
incorporated [3H]thymidine as average counts of triplicate wells.
Co op: codon optimized; MCR: codon-optimized plus mouse
constant region. B) Flow cytometry analysis of CD137 (4-1BB)
expression in TCR-5-transduced T cells upon coculture with
HLA-A*0201+ SSX2+ or HLA-A*0201+ SSX2- cells (Cos-A2-
SSX2 and Cos-A2, respectively). Staining with anti-CD8 and anti
CD137 antibodies was performed after an overnight coculture. C)
Flow cytometry analysis of IFNg and IL-2 expression in TCR-5-
transduced T cells upon coculture with HLA-A*0201- SSX2+ or
HLA-A*0201+ SSX2+ cell lines (938 and 938-A2, respectively).
Gated on CD3+ cells.
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